NO911752L - Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester. - Google Patents

Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester.

Info

Publication number
NO911752L
NO911752L NO91911752A NO911752A NO911752L NO 911752 L NO911752 L NO 911752L NO 91911752 A NO91911752 A NO 91911752A NO 911752 A NO911752 A NO 911752A NO 911752 L NO911752 L NO 911752L
Authority
NO
Norway
Prior art keywords
proteins
polypeptides
somatotropines
cystein
stabilization
Prior art date
Application number
NO91911752A
Other languages
English (en)
Norwegian (no)
Other versions
NO911752D0 (no
Inventor
Brian Lee Buckwalter
Susan Mancini Cady
Michael Joseph Daley
Hong-Ming Shieh
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO911752D0 publication Critical patent/NO911752D0/no
Publication of NO911752L publication Critical patent/NO911752L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO91911752A 1990-05-04 1991-05-03 Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester. NO911752L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51904790A 1990-05-04 1990-05-04

Publications (2)

Publication Number Publication Date
NO911752D0 NO911752D0 (no) 1991-05-03
NO911752L true NO911752L (no) 1991-11-05

Family

ID=24066559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911752A NO911752L (no) 1990-05-04 1991-05-03 Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester.

Country Status (17)

Country Link
EP (1) EP0458064B1 (de)
JP (1) JPH069696A (de)
KR (1) KR100213455B1 (de)
AT (1) ATE163431T1 (de)
AU (1) AU639324B2 (de)
CA (1) CA2041742A1 (de)
DE (1) DE69128944T2 (de)
DK (1) DK0458064T3 (de)
ES (1) ES2113354T3 (de)
FI (1) FI912144A7 (de)
GR (1) GR3026436T3 (de)
IE (1) IE911511A1 (de)
IL (1) IL97932A (de)
NO (1) NO911752L (de)
NZ (1) NZ237959A (de)
PT (1) PT97539B (de)
ZA (1) ZA913359B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB9100381D0 (en) * 1991-01-09 1991-02-20 Erba Carlo Spa Human bfgf derivatives,their analogs and process for their production
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
CA2124672A1 (en) * 1991-12-10 1993-06-24 Tse W. Chang Cytokines with an upaired cysteine residue and conjugates thereof
EP0679095A1 (de) * 1992-11-25 1995-11-02 Amgen Boulder Inc. Modifizierte insulinartigen wachtstumfaktor
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
US8329866B2 (en) 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
ES2154627T3 (es) * 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof

Also Published As

Publication number Publication date
ES2113354T3 (es) 1998-05-01
KR910020032A (ko) 1991-12-19
DE69128944D1 (de) 1998-04-02
JPH069696A (ja) 1994-01-18
AU639324B2 (en) 1993-07-22
IE911511A1 (en) 1991-11-06
DE69128944T2 (de) 1998-06-25
ATE163431T1 (de) 1998-03-15
CA2041742A1 (en) 1991-11-05
NZ237959A (en) 1994-05-26
NO911752D0 (no) 1991-05-03
EP0458064A3 (en) 1992-06-17
PT97539B (pt) 1998-08-31
EP0458064A2 (de) 1991-11-27
AU7607591A (en) 1991-11-07
FI912144L (fi) 1991-11-05
DK0458064T3 (da) 1998-04-27
IL97932A (en) 1998-02-22
ZA913359B (en) 1992-03-25
PT97539A (pt) 1992-02-28
FI912144A7 (fi) 1991-11-05
IL97932A0 (en) 1992-06-21
FI912144A0 (fi) 1991-05-03
GR3026436T3 (en) 1998-06-30
EP0458064B1 (de) 1998-02-25
KR100213455B1 (ko) 1999-08-02

Similar Documents

Publication Publication Date Title
NO911752D0 (no) Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester.
DK0469074T3 (da) Cystein-tilsatte varianter af IL-3 og kemiske modifikationer deraf
EP0355460A3 (de) Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
DK358384D0 (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
MD960317A (ro) Noile peptide-agoniste ale amilinei şi utilizarea lor
DK447788A (da) Apparat til applikation af implantater
ATE394423T1 (de) Analoge des glucagon ähnlichen peptides-1 (glp-1)
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
DK169784D0 (da) Peptider til farmaceutisk behandling af pattedyr
NO922953L (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
UA42040C2 (uk) Поліпептид, спосіб діагностики інсулінозалежного цукрового діабету (iddm), що розвинувся або що розвивається (варіанти), набір для діагностики iddm (варіанти), препарат для запобігання або лікування iddm, фармацевтична композиція для профілактики або лікування iddm
DE59209525D1 (de) Neues rekombinantes Human-IFN-beta, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zubereitungen
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
BR9307687A (pt) Análogos de insulina
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
SE8200757L (sv) Biologiskt aktiva peptider
DE69333261D1 (de) KLONIERUNG UND EXPRESSION VON DEM beta APP-C100 REZEPTOR
YU64192A (sh) Analozi insulina
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
Yajima et al. Synthesis of the nonacosapeptide corresponding to the entire amino acid sequence of duck glucagon
DE69623464D1 (de) Modifizierte kojibioside analoge
NO177536C (no) HIV-1-relaterte polypeptider, preparat som omfatter en blanding med minst to polypeptider, samt diagnostisk system og anvendelse av et polypeptid for måling av anti-HIV-1-antistoffer
NO873751L (no) Lymfocytt-aktiverende polypeptider.